Citable filing context
IFF's research view summarizes recent SEC filing context, starting with earnings from Aug 4, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 4, 2026 | earnings | IFF reported second quarter 2026 financial results and announced an enhanced $2.5 billion share repurchase authorization. |
| Aug 4, 2026 | divestiture | IFF is selling its Food Ingredients business to CVC Capital Partners, retaining a 10% minority equity interest. |
| Jun 23, 2026 | debt_offering | IFF entered into a $1.0 billion senior unsecured term loan credit facility to refinance €800 million of senior notes. |
| Aug 4, 2026 | Guidance: adjusted_operating_ebitda | 1530.00 to 1600.00 |
| Aug 4, 2026 | Guidance: comparable_currency_neutral_adjusted_operating_ebitda_growth | 4.00 to 8.00 |
| Aug 4, 2026 | Guidance: comparable_currency_neutral_sales_growth | 2.00 to 4.00 |
| Aug 4, 2026 | mda_quarterly | International Flavors & Fragrances (IFF) reported second-quarter 2026 net sales of $1.95 billion, a 2% increase on a reported basis and 6% on a comparable currency-neutral basis. Growth was driven by volume and price increases across its three core segments: Taste, Health & Biosciences, and Scent. Gross profit rose 4% to $853 million, benefiting from productivity gains and tariff refunds, despite portfolio shifts. The company is undergoing a significant strategic transformation, highlighted by the pending divestiture of its Food Ingredients business to CVC Capital Partners, expected to close by mid-2027. This follows the 2025 divestitures of its Pharma Solutions and Nitrocellulose businesses. Consequently, IFF has reclassified these units as discontinued operations. Financial health remains a focus, with interest expense declining 25% year-over-year due to reduced debt levels. The company maintains a net debt-to-credit-adjusted EBITDA ratio of 2.51x. To enhance shareholder value, the Board authorized a $2.5 billion share repurchase program, including an immediate $500 million accelerated buyback. Key risks include ongoing regulatory investigations into anticompetitive conduct in the fragrance industry and potential volatility in input costs. Management continues to prioritize capital allocation toward debt reduction and strategic investments while navigating complex global tax and regulatory environments. |
| May 5, 2026 | mda_quarterly | First-quarter 2026 net sales reached $2.741 billion, a 4% reported decrease but a 3% increase on a comparable currency-neutral basis. Net income recovered to $170 million from a $1.017 billion loss in the prior year, which was primarily driven by a $1.153 billion goodwill impairment in the Food Ingredients segment. Comparable currency-neutral growth was strongest in Health & Biosciences (5% sales) and Taste (2% sales), while the Scent segment experienced a 2% decline in adjusted operating EBITDA as unfavorable pricing in Fragrance Compounds offset volume gains. IFF continues portfolio optimization, completing the divestiture of the Soy Crush, Concentrates, and Lecithin business for $105 million and executing a productivity program with estimated costs between $110 million and $130 million to reduce headcount and close plants. The company maintains a net debt to credit adjusted EBITDA ratio of 2.53x and is utilizing a $500 million share repurchase program. Significant risks include ongoing antitrust investigations into fragrance businesses by the European Commission, UK Competition and Markets Authority, and the U.S. Department of Justice, alongside legacy litigation stemming from the Frutarom acquisition. |
Source: SEC EDGAR filing text and events; period Aug 4, 2026; filed Aug 4, 2026.
IFF company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.